Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.60 |
| ▸ | DHODH | Q02127 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23041828 | 0.84 | SMN1; SMN2 (0.54) | SLC6A2SLC6A4SLC6A3DHODHHRH3 | |
| SCHEMBL16861681 | 0.83 | HRH3 (0.53) | SLC6A2SLC6A4SLC6A3HRH3ALDH1A1 | |
| SCHEMBL21788564 | 0.83 | TDP1 (0.47) | SLC6A2SLC6A4SLC6A3ALDH1A1SMN1; SMN2 | |
| SCHEMBL14390178 | 0.80 | SLC6A4 (0.54) | SLC6A2SLC6A4SLC6A3ALDH1A1SMN1; SMN2 | |
| SCHEMBL10021103 | 0.79 | DHODH (0.58) | DHODHHRH3SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13232178 | 0.79 | DHODH (0.58) | SLC6A2SLC6A4SLC6A3DHODHHRH3 | |
| SCHEMBL1042296 | 0.79 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3ALDH1A1SMN1; SMN2 | |
| SCHEMBL20970365 | 0.78 | SLC6A2 (0.75) | SLC6A2SLC6A4SLC6A3ALDH1A1SMN1; SMN2 | |
| SCHEMBL9327579 | 0.78 | CHRM2 (0.49) | SLC6A2SLC6A4SLC6A3HRH3CHRM2 | |
| SCHEMBL8036930 | 0.77 | DHODH (0.56) | DHODHHRH3ALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1249447-B1 | Intermediate for the production of 1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol | ALEMBIC LTD (IN) | 2008-10-22 | — | — | EP | claimed |
| US-6756502-B2 | AS CHEMICAL INTERMEDIATE IN PREPARATION OF VENLAFAXINE | ALEMBIC LIMITED (IN) | 2004-06-29 | — | — | US | claimed |
| US-20030195376-A1 | Novel intermediate and processes for its preparation and conversion into a pharmacologically-active agent | ALEMBIC LIMITED (A CORPORATION OF INDIA) (IN) | 2003-10-16 | — | — | US | claimed |
| EP-1249447-A1 | Intermediate for the production of 1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol | Alembic Limited (IN) | 2002-10-16 | — | — | EP | claimed |
| EP-1249447-B1 | Intermediate for the production of 1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol | ALEMBIC LTD (IN) | 2008-10-22 | — | — | EP | disclosed |
| EP-1249447-B1 | Intermediate for the production of 1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol | ALEMBIC LTD (IN) | 2008-10-22 | — | — | EP | disclosed |
| US-6756502-B2 | AS CHEMICAL INTERMEDIATE IN PREPARATION OF VENLAFAXINE | ALEMBIC LIMITED (IN) | 2004-06-29 | — | — | US | disclosed |
| US-20030195376-A1 | Novel intermediate and processes for its preparation and conversion into a pharmacologically-active agent | ALEMBIC LIMITED (A CORPORATION OF INDIA) (IN) | 2003-10-16 | — | — | US | disclosed |
| EP-1249447-A1 | Intermediate for the production of 1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol | Alembic Limited (IN) | 2002-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195376-A1 | Novel intermediate and processes for its preparation and conversion into a pharmacologically-active agent | CYP3A4, CYP4X1, CYP2F1 | SLC6A2 211/4885SLC6A4 41/4885SLC6A3 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.